Sitting at a market capitalization of $159 billion, Amgen (AMGN) is a biotech powerhouse. Founded in 1980, it is one of the biggest names in the healthcare and biotech industry, with a strong history ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Amgen (NASDAQ:AMGN – Get Free Report) had its target price raised by Bank of America from $256.00 to $275.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “underperform” ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...